Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Talzenna

(tal-ZEH-nuh)
A drug used alone to treat adults with HER2-negative breast cancer that has spread and has certain mutations (changes) in the BRCA1 or BRCA2 gene and with enzalutamide to treat adults with prostate cancer that has spread, has not responded to treatments that lower testosterone levels, and has a mutation in the HRR gene. It is also being studied in the treatment of other types of cancer. Talzenna blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. Talzenna is a type of PARP inhibitor. Also called talazoparib tosylate.
More Information
Search NCI's Dictionary of Cancer Terms